BMCS vs PCRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMCS is a Hold and PCRX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMCS’s FA Score shows that 0 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).
- BMCS’s FA Score: 0 green, 5 red.
- PCRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCRX’s TA Score shows that 3 TA indicator(s) are bullish.
- PCRX’s TA Score: 3 bullish, 5 bearish.
Price Growth
BMCS (@Pharmaceuticals: Other) experienced а +93.00% price change this week, while PCRX (@Pharmaceuticals: Other) price change was -7.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +56.20%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -6.95%.
Reported Earning Dates
PCRX is expected to report earnings on Feb 27, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+56.20% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BMCS | PCRX | BMCS / PCRX | |
| Capitalization | N/A | 1.36B | - |
| EBITDA | N/A | 155M | - |
| Gain YTD | -46.240 | -51.482 | 90% |
| P/E Ratio | N/A | 32.74 | - |
| Revenue | N/A | 675M | - |
| Total Cash | N/A | 279M | - |
| Total Debt | N/A | 586M | - |
BMCS | PCRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 83 | |
PRICE GROWTH RATING 1..100 | 54 | 61 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMCS's Valuation (36) in the null industry is in the same range as PCRX (56) in the Pharmaceuticals Other industry. This means that BMCS’s stock grew similarly to PCRX’s over the last 12 months.
BMCS's Profit vs Risk Rating (100) in the null industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that BMCS’s stock grew similarly to PCRX’s over the last 12 months.
PCRX's SMR Rating (83) in the Pharmaceuticals Other industry is in the same range as BMCS (100) in the null industry. This means that PCRX’s stock grew similarly to BMCS’s over the last 12 months.
BMCS's Price Growth Rating (54) in the null industry is in the same range as PCRX (61) in the Pharmaceuticals Other industry. This means that BMCS’s stock grew similarly to PCRX’s over the last 12 months.
BMCS's P/E Growth Rating (100) in the null industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that BMCS’s stock grew similarly to PCRX’s over the last 12 months.
| PCRX | |
|---|---|
| RSI ODDS (%) | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 80% |
| Advances ODDS (%) | 9 days ago 0% |
| Declines ODDS (%) | 1 day ago 78% |
| BollingerBands ODDS (%) | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 72% |
BMCS and
Correlation & Price change
A.I.dvisor tells us that BMCS and PCRX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMCS and PCRX's prices will move in lockstep.
| Ticker / NAME | Correlation To BMCS | 1D Price Change % | ||
|---|---|---|---|---|
| BMCS | 100% | -0.52% | ||
| PCRX - BMCS | 28% Poorly correlated | -0.49% | ||
| CLCFF - BMCS | 16% Poorly correlated | -13.49% | ||
| LOVFF - BMCS | 12% Poorly correlated | N/A | ||
| CRYM - BMCS | 5% Poorly correlated | +18.93% | ||
| INNPF - BMCS | 5% Poorly correlated | -0.47% | ||
More | ||||
PCRX and
Correlation & Price change
A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.
| Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
|---|---|---|---|---|
| PCRX | 100% | -0.49% | ||
| ELAN - PCRX | 31% Poorly correlated | -1.06% | ||
| TEVA - PCRX | 29% Poorly correlated | -1.12% | ||
| BMCS - PCRX | 29% Poorly correlated | -0.52% | ||
| NBIX - PCRX | 25% Poorly correlated | -2.10% | ||
| ESPR - PCRX | 23% Poorly correlated | -5.83% | ||
More | ||||